Prof. Giovanni Meola - lamadonnina.grupposandonato.it · curriculum vitae prof. giovanni meola 1 curriculum vitae et studiorum giovanni meola professore ordinario di neurologia universitÀ

CURRICULUM VITAE Prof. Giovanni Meola

1

CURRICULUM VITAE ET STUDIORUM Giovanni Meola

PROFESSORE ORDINARIO DI NEUROLOGIA UNIVERSITÀ DEGLI STUDI DI MILANO

DIRETTORE UNITÀ OPERATIVA COMPLESSA DI NEUROLOGIA E STROKE-UNIT IRCCS POLICLINICO SAN DONATO

DIRETTORE SCUOLA DI SPECIALIZZAZIONE DI NEUROLOGIA UNIVERSITÀ DEGLI STUDI DI MILANO

ISTRUZIONE E FORMAZIONE − Nato a Potenza il 25 giugno 1949 − Laureato in Medicina e Chirurgia a pieni voti assoluti (1973) presso l’Università degli Studi di

Milano. − Abilitazione alla professione di Medico-Chirurgo nell’anno 1974. − Idoneità per concorso a contratti liberi, quadriennali, presso la Clinica Psichiatrica dell’Università

degli Studi di Milano, Istituto Psichiatrico Provinciale “Paolo Pini”, 1976. − Specializzazione in Neurologia conseguita il 18 novembre 1977 presso l’Università degli Studi di

Milano. − Conseguimento dell’Idoneità a Primario di Neurologia nella sessione dell’anno 1986. − Vincitore di due borse di studio: nel 1974 presso il Regional Neurological Centre, General Hospital

di Newcastle Upon Tyne, diretto dal Prof. J.N.Walton. e nel 1979 presso il Department of Neurology, College of Surgeons and Physicians della Columbia University di New York – USA.

− Stages di specializzazione negli anni 1974, 1975 e 1978 rispettivamente presso il Muscular Dystrophy Research Laboratories – Regional Neurological Centre - Newcastle General Hospital – Newcastle Upon Tyne (England), sotto la guida del Prof. J.N.Walton.

− Stages di ricerca negli anni 1980 e 1981 presso l’ “Houston Merritt Clinical Research Centre for the Study of Muscular Dystrophy and Related Diseases”, e presso il “Tissue Culture Laboratory at the Houston Merritt Muscle Centre of Columbia University, College of Physicians & Surgeons”, University of Columbia, New York, N.Y. (USA).

− Nel 1991 stages di ricerca presso il Montreal Neurological Institute, Neuromuscular Group, Montreal (Canada), sotto la guida del Prof. G.Karpati e presso il Department of Anatomy, Laval University” l’Hopital de l'Enfant Jesus – Quebec (Canada), sotto la guida delProf.J.P.Tremblay

− Dal 1988 ad oggi, partecipazione annuale ai Corsi di formazione dell’American Academy of Neurology (AAN) – USA

ATTIVITA’ LAVORATIVA − Medico Interno dell’istituto di Clinica delle Malattie Nervose e Mentali dell’Università degli Studi

di Milano, dal 1 Gennaio 1974 al 30 Giugno 1975. − Assistente Universitario Incaricato presso la Cattedra di Clinica delle Malattie Nervose e Mentali

dell’Università degli Studi di Milano dal 1 Marzo 1975. − Assistente Ordinario presso la Cattedra di Clinica Neurologica dell’Università degli Studi di

Milano dal 1° Febbraio 1980. − Professore Associato di Neurologia presso l’Università degli Studi di Milano dal 1° Gennaio 1986. − Professore Associato di Neurologia Confermato presso l’Università degli Studi di Milano dal

1°Gennaio 1989.


2

− Aiuto Universitario presso la Clinica Neurologica – Pad. Ponti – Ospedale Maggiore – Policlinico dal 1986 al 1991.

− Professore Ordinario dal 2001 presso l’Università degli Studi di Milano e titolare del corso di Malattie del Sistema Nervoso presso il Corso di laurea di Medicina e Chirurgia dell’Università degli Studi di Milano dal 1986.

− Primario della Divisione di Neurologia II dell’IRCCS Policlinico San Donato dal Gennaio 1992, su designazione del Consiglio di Facoltà di Medicina e Chirurgia dell'Università degli Studi di Milano.

− Direttore del Dipartimento di Neurologia e Primario della Divisione di Neurologia dell’IRCCS Policlinico San Donato, dall’Aprile 1994.

− Direttore della Stroke-Unit, IRCCS Policlinico San Donato, dal 2006. − Dal 1995 ad oggi è visiting Professor, con frequenza annuale e permanenza di 3-6 giorni, presso il

Department of Neurology, University of Rochester, Rochester - N.Y. (USA) ed è membro del Muscle Study Group (MSG) con riunioni annuali presso Centri Neuromusculari americani.

− Dall’anno 1995 ad oggi è relatore di casi clinici ai Corsi Neuromuscolari dell’American Academy of Neurology.

− Dal 2009 è visiting Professor presso l’Università di Belgrado – Serbia − Nel 2010 direttore e relatore del Corso “Update of Myotonias” nell’ambito dell’American

Academy of Neurology (AAN). − Dal 2013 Direttore della Scuola di Specializzazione in Neurologia, Università degli Studi di

Milano − Dal 2013 Membro Interno del Comitato Etico – IRCCS Ospedale San Raffele, Milano.

ATTIVITA’ DI REVISORE PER RIVISTE INTERNAZIONALI − Membro del Board Editoriale: European Journal of Histochemisytry, Neurological Sciences,

Neuromuscular Disorders − Revisore per riviste internazionali: Acta Neurologica Scandinavica, Am J Med Genetics – NPG,

Am J Med Genetics – NPS, Annals of Neurology, ANR, BBA, Brain, Cochrane Library, European Journal of Neurology, Eur J Pharm, Eur J Cell Biol, FEBS letter, Gene Reviews, Human Mol Genet, Journal of Neurology, Neurosurgery and Psychiatry, Journal of the Neurological Sciences, Muscle & Nerve, Neurobiology of Disease, Neurological Science, Neurology, Neuro Therapeutics, Physiological Measurement, PNAS, PlosOne

− Revisore per progetti di ricerca internazionali: AFM, Muscular Dystrophy Campaign, The French Institute for Research on Rare Diseases, The French National Research Agency (ANR)

MEMBRO DI SOCIETA’ SCIENTIFICHE IN AMBITO NAZIONALE ED INTERNAZIONALE − Società internazionali. American Academy of Neurology (AAN), American Neurological

Association (ANA), European Academy of Neurology (EAN), American Tissue Culture Association, World Muscle Society (WMS)

− Società Nazionali: Società Italiana di neurologia (SIN), Società Italiana di Neuropatologia, Società Italiana di Miologia (AIM) – Società Italiana di Istochimica – Membro del Centro Dino Ferrari per le malattie neurogenenerative - MI, Fondatore e Presidente CMN (Centro per lo studio delle Malattie Neuromuscolari), Fondatore e Presidente FMM (Fondazione Malattie Miotoniche)

ATTIVITA’ ORGANIZZATIVA DI CONVEGNI NAZIONALI ED INTERNAZIONALI Nazionali − Dal 1992 ad oggi, organizzatore di Seminari di Neurologia denominati “Martedì di San Donato”


3

− Nel 2010 organizzatore e Chairman del 10° Congresso AIM (Società Italiana di Miologia)– Milano, 3-5 Giugno 2010

Internazionali − Co-organizzatore del 54th ENMC International Workshop: PROMM and other − Proximal Myotonic Sindrome – 2007 Netherland − Co-organizzatore del 84th ENMC International Workshop: PROMM and other Proximal Myotonic

Sindrome – Netherland 2000 − Co-organizzatore del 115th ENMC International Workshop: DM2/PROMM and other myotonic

dystrophies – Netherland 2003 − Co-organizzatore del 140th ENMC International Workshop: Myotonic dystrophy DM2/PROMM

and other Myotonic dystrophies with guidelines on management – Netherland 2006 − Organizzatore e Chairman dell’IDMC-6 (International Myotonic Dystrophy Consortium Meeting

– 6); Milano, 12-15 Settembre 2007 − Organizzatore del 1° Workshop “Cerebral Involvement in Myotonic Dystrophy type I and II”;

Parigi, Institute de Myologie – Hôpital la Salpetrière; 29 gennaio 2010 − Organizzatore del 2° Workshop “Cerebral Involvement in Myotonic Dystrophy type I and II”;

Parigi, Institute de Myologie – Hôpital la Salpetrière; 24-25 febbraio 2011 − Organizzatore del 4° Workshop “Cerebral involvement in Myotonic Dystrophy type I and II”;

Ferrere (AT), 24-27 maggio 2013. − Organizzatore del 5° Workshop “Cerebral involvement in Myotonic Dystrophy type I and II”;

Milano, 2-3 dicembre 2014. − Curatore della traduzione italiana del libro “Myotonic dystrophy – The Fact” di P. Harper. 2° ed.

2013.

PREMI

− Vincitore del premio “Clinical Science Award” in occasione dell’IDMC-9; San Sebastian 16-18 ottobre 2013.

− Vincitore del premio “Gaetano Conte” in Clinical Research in Myology; Atene 1 novembre 2013.

ATTIVITA’ DIDATTICA − È titolare del Corso Integrato “MALATTIE DEL SISTEMA NERVOSO” Corso di Laurea in

Medicina e Chirurgia, Università degli Studi di Milano, Facoltà di Medicina e Chrurgia, Polo Didattico Centrale – LINEA 1 San Donato

− Espleta l’attività didattica al Corso di Laurea in Medicina e Chirurgia dell’Università degli Studi di Milano in diversi Corsi di Specializzazione (Neurologia, Psichiatria, Urologia, Ortopedia, Medicina Fisica e Riabilitazione, Geriatria, Genetica Medica) e di Lauree brevi (Salute dell’adulto e dell’anziano) e presso altre Università italiane ed internazionali

ATTIVITA’ CLINICA −− Nell'ambito dell’attività Clinica e Assistenziale, oltre alla direzione dell'Unità Operativa

Complessa di Neurologia del IRCCS Policlinico San Donato, coordina: oo attività ambulatoriali di Neurologia Generale, Malattie Neuromuscolari e del Sistema

Extrapiramidale, Centro delle Cefalee e Servizi annessi alla Divisione di Neurologia (laboratorio di istopatologia muscolare e di neurochimica);

oo il Centro Provinciale per la diagnosi e la cura della Sclerosi Multipla, riconosciuto a livello nazionale, per la distribuzione del β-interferone nella variante R/R della Sclerosi Multipla;


4

oo l’ambulatorio specialistico “UVA” – Unità di Valutazione Alzheimer, nell’ambito del progetto Cronos del Ministero della Sanità;

oo è responsabile dal 1999 di una Unità di Ricerca di un Progetto Nazionale sulle “Canalopatie muscolari”;

oo dal giugno 2006 è Responsabile della Unità di Stroke Unit del IRCCS Policlinico San Donato. oo dal 2010 è Responsabile del Laboratorio di Istopatologia Muscolare e Biologia Molecolare,

presso l’IRCCS Policlinico San Donato.

ATTIVITA’ DI RICERCA FINANZIATA

Progetto di ricerca Telethon: Dystrophin expression in muscle clones from asymptomatic DMD carriers: possible application for carrier detection

1991 Lire 30.000.000

Progetto di ricerca dell’Università a carattere nazionale (MURST): Clinical and electrophysiological approach in myotonias due alteration of chloride channelopathies

1998 Lire 58.000.000

Progetto di ricerca dell’Università a carattere nazionale (MURST): Clinical, histopathological and electrophysiological study in non-dystrophic myotonias.

1999 Lire 86.000.000

Progetto di ricerca dell’Università a carattere nazionale (MURST): Multisystemic study and gene defect localization in PROMM.

1999-2001 Lire 70.000.000

Progetto Speciale di ricerca dell’Università a carattere nazionale (COFIN-PRIN): Phenotype-genotype correlation in hereditary channelopathies.

2001-2003 Euro 48.446,00

Progetto di ricerca dell’Università di Milano (FIRST): Effect of mexiletine in myotonic dystrophies and chloride, sodium channelopathies.

2001-2002 Euro 9.595,00

Progetto di ricerca dell’Università di Milano (FIRST): Quantification of myotonia: QMA 2003 Euro 2.803,00

Progetto di ricerca dell’Università di Milano (FIRST): Registry, natural history and QMA in neuromuscular disease.

2001-2005 Euro 25.000,00

Progetto di ricerca dell’Università a carattere nazionale (COFIN-PRIN): DM1 and DM2 from pathogenesis to gene therapy.

2005-2007 Euro 34.000,00

Progetto AFM: Innovative therapeutic approaches to Myotonic Dystrophy Type 1 and 2 (Co-PI)

2008-2010 Euro 40.000,00

Rinnovo Progetto AFM: Innovative therapeutic approaches to Myotonic Dystrophy Type 1 and 2 (Co-PI)

2011-2013 Euro 40.000,00

Progetto Ministero della Salute: Registro Nazionale delle distrofie miotoniche 2013 Euro 150.00,00

Progetto Telethon: Ruolo dei microrna nel muscolo scheletrico e nel sangue circolante dei malati di Distrofia Miotonica di tipo 1 (Co-PI)

2013-2016 Euro 345.300,00

Progetto AFM-Telethon: MicroRNA function and use as biomarkers in Myotonic Dystrophy type 1 (Co-PI)

2014

2015 Euro 90.000,00

Progetto MDF: A new approach of pathomolecular mechanism in myotonic dystrophy insulin resistence by nutrigenomics

2016-2017 $ 110.000


5

ATTIVITA’ SCIENTIFICA

L’attività scientifica si è concretizzata in 220 pubblicazioni su riviste citate dallo JCR (Journal Citation Report), dall’IM (Index Medicus) e con board internazionale e referee; 62 lavori pubblicati su riviste nazionali ed internazionali; 42 capitoli, di cui 28 pubblicati su testi internazionali). Più di 400 abstact presentati a convegni nazionali ed internazionali e più di 250 letture e seminari su invito.

L’Impact Factor è di 692,541. H-index: 32 con 3500 citazioni su 205 documenti.

La produzione scientifica si è articolata durante gli anni su diversi filoni di ricerca che possono essere sintetizzati nei seguenti punti: Area Sclerosi multipla −− BEST PGx Study (Betaferon in Early Relapsing –Remitting Multiple Sclerosis Surveillance Trial

Pharmacogenomic and Pharmacogenic Study – Studio di sorveglianza clinica e di farmacogenomica in pazienti affetti da SM in fase remittente, recidivante in terapia con Betaferon) in collaborazione con University Hospitals Basel – Basilea – Svizzera - Prof. L. Kappos.

−− Progetto ASPIRE (Studio clinico IFNB-1b per la “Evoluzione della disabilità e monitoraggio concomitante della componente infiammatoria in pazienti con sclerosi multipla secondariamente progressiva trattati con Azatioprina o placebo e con Interferone”) in collaborazione con Divisione di Neurologia – Ospedale di Fidenza – Dr. Montanari.

−− Studio sull’espressione di molecole di adesione su sottopopolazioni linfocitarie CD8+ in pazienti affetti da SM tipo RR trattati con Interferone beta 1b. In collaborazione con prof. Battistini – Università di Roma.

−− Studio di confronto Betaferon e Betaferon + Metilprednisolone nelle forme Secondarie progressive di Sclerosi Multipla.

−− Messa a punto di un protocollo quantitativo della “fatica muscolare” mediante apposita apparecchiatura computerizzata (QMA) in pazienti affetti da Sclerosi Multipla.

Area Neuromuscolare −− studio istoenzimologico-istochimico muscolare e tecniche quantitative istografiche; −− studio di membrana nella Distrofia Muscolare di Duchenne (DMD), nelle portatrici di DMD e

nella Corea di Huntington mediante impiego di sonde fluorescenti; −− allestimento di “colture in vitro” di mioblasti umani normali e patologici; −− messa a punto di protocolli clinici-diagnostici e identificazione di mutazioni puntiformi nelle

famiglie con fenotipo di canalopatie neurologiche ereditarie; −− studio multisistemico e identificazione di nuove famiglie italiane con fenotipo PROMM (miopatia

miotonica prossimale); −− correlazione tra il genotipo-fenotipo nelle miotonie non distrofiche; −− impiego del set “QMA” (quantitative muscle assessment) in trials clinici, nelle malattie

neuromuscolari; Area Neurodegenerativa − Progetto CHRONOS (Unità valutative Alzheimer e malattie correlate (UVA) – Progetto

Ministeriale − Progetto SIRIO (Stroke in Italy and Related Impact on Outcome). Registro Nazionale dell’Ictus. In

collaborazione con la Divisione di Neurologia, Ospedale di Treviso, Prof. V. Toso Area extrapiramidale − Studio del metabolismo della L-Dopa in pazienti parkinsoniani.


6

COLLABORAZIONI NAZIONALI ED INTERNAZIONALI

Nazionali − Università degli Studi di Milano – Dipartimento di Scienze Biomolecolari e Biotecnologie, Prof. E.

Mancinelli. − Università degli Studi di Milano – Centro Dino Ferrari – Policlinico, Prof. G. Comi. − Università degli Studi di Pavia – Istituto Neurologico Mondino, Prof. G. Nappi. − Università degli Studi di Pavia - Dipartimento di Biologia, Prof. C. Pellicciari. − Università degli Studi di Padova – Dipartimento di Neuroscienze, Prof. C. Angelini. − Università degli studi di Torino – Dipartimento di Neuroscienze, Prof. T. Mongini. − Università degli Studi di Bologna – Dipartimento di Neuroscienze, Prof. R. Liguori. − Divisione di Neurologia – Ospedale di Fidenza, Dr. Montanari. − Università degli Studi di Siena – Dipartimento di Neuroscienze, Prof. A. Federico. − Università degli Studi di Pisa – Dipartimento di Neuroscienze, Prof. G. Siciliano. − Università degli Studi Tor Vergata – Dipartimento di Genetica e di Neuroscienze. Proff. G. Novelli

e R. Massa . − Università degli studi di Napoli – Dipartimento di Genetica, Prof. L. Politano. − Università degli Studi di Messina – Dipartimento di Neuroscienze, Prof. A. Toscano.

Internazionali − Università di Rochester (NY) USA, Proff. RT Moxley, C. Thornton. Area Neuromuscolare − Consorzio Internazionale sulle Canalopatie (CINCH), Prof. RC Griggs (USA). Area

Neuromuscolare − Dipartimento di Biologia Cellulare – Università di Laval (Quebec) Canada, Prof. J Puymirat . Area

Neuromuscolare − Marigold Foundation – Calgary (Canada). Area Neuromuscolare − Baylor College - Università di Houston (USA) – Dipartimento di Biologia, Prof. L. Timchenko.

Area Neuromuscolare − London College University – Londra (GB) – Dipartimento di Neuroscienze, Prof. M. Hanna. Area

Neuromuscolare − Università di Helsinki (Finlandia), Proff. B. Hudd e A. Vhiola. Area Neuromuscolare − Università di Goteborg (Svezia), Prof. S. Winblad. Area Neuromuscolare − Università di Parigi – Necker-Enfants (Francia), Proff. G. Gourdon e M. Gomes-Pereira. Area

Neuromuscolare − Università di Parigi – Hopital La Salpetriere (Francia), Proff. B. Eymard e B. Fontaine. Area

Neuromuscolare − Università di Belgrado (Serbia) – Dipartimento di Neurologia – Stage di un ricercatore presso la

UOC di Neurologia e il Laboratorio di Patologia Neuromuscolare – IRCCS Policlinico San Donato ALTRO

− Fondatore e Presidente del Centro per lo Studio delle Malattie Neuromuscolari (CMN), dal luglio 2004.

− Fondatore e Presidente della Fondazione Malattie Miotoniche (FMM) dal 2011.

− Membro permanente del Comitato Etico dell’Ospedale San Raffaele


7

Pubblicazioni scientifiche su riviste citate dal JCR (Journal Citation Report), dall’Index Medicus (I.M.) e con board internazionale e referee

1. Aporti F, Caccia MR, Finesso M, Meola G, Scarlato G: "Effects of the brain cortex gangliosides

on motor unit regeneration in rats". Electroenceph. Clin. Neurophysiol., 43: 588-589, 1977. I.F. 2.450

2. Capitani E, Meola G, Spinnler H: "Amyotrophy and Kluever-Bucy Syndrome. A case report." European Neurology, 16: 99-105, 1977. I.F. 1.179

3. Scarlato G, Valli G, Meola G, Carenini L: "Quantitative EMG and histological carrier detection

of Duchenne muscular dystrophy". J. Neurol., 216: 235-249, 1977. I.F. 2.653 4. Caccia MR, Cerri C, Gravame G, Meola G, Pagni R, Scarlato G, Scarpini E: "Myopathy with

paroxysmal myoglobinuria and focal muscle necrosis following enfluorane anaesthesia". J. Neurol Sci, 39: 61-69, 1978. I.F. 1.986

5. Caccia MR, Meola G, Brignoli G, Andreussi L, Scarlato G: "Physiological and hystochemical

changes of the extensor digitorum longus (EDL) and soleus muscles after lateral cordotomy in the albino rat". Exp Neur, 62: 647-657, 1978. I.F. 3.503

6. Scarlato G, Meola G: "Chronic myopathy with cytoplasmatic bodies in the pig". J. Comp. Path.,

88: 31-37, 1978. I.F. 1.543 7. Scarlato G, Meola G, Scarpini E, Cerri C: "Muscular carnitine synthesis and palmitate

metabolism in vitro". J. Neurol., 218: 149-156, 1978. I.F. 2.653 8. Scarlato G, Pellegrini G, Cerri C, Meola G, Veicsteinas A: "The syndrome of carnitine

deficiency: morphological and metabolic correlation in two cases". Canad. J. Neurol. Sci., 5: 205-213, 1978. I.F. 1.317

9. Caccia MR, Meola G, Cerri C, Frattola L, Scarlato G, Aporti F: "Treatment of denervated

muscle by gangliosides". Muscle and Nerve, 2:382-389,1979. I.F. 2.316 10. Scarlato G, Meola G, Silani V, Manfredi L, Bottiroli G, Zanella A: "Erytrocyte

spectrofluorometric abnormalities in Duchenne patients and carriers. A new approach to carrier detection". Acta Neurologica Scandinavia, 59: 262-269, 1979. I.F. 1.064

11. Mariani C, Albizzati MG, Boni S, Bassi S, Meola G: "Type II atrophy in pentazocine addicted

patient". Italian J. Neurol. Sci., 2: 115-118, 1980. I.F. 0,521 12. Meola G, Manfredi L, Scarpini E, Dall'Oglio P, Mariani C, Scarlato G: "Pentazocine-induced

neuromuscular syndrome: clinical, histochemical features in two cases and a tissue culture study of pentazocine-blocked myogenesis in human foetal muscle". Basic and Appl. Histoch. , 24: 183-202, 1980. I.F. 0.954

13. Zanella A, Izzo C, Meola G, Mariani MG, Colotti MT, Silani V, Pellegata G, Scarlato G:

"Metabolic impairment and membrane abnormality in red cells from Huntington's disease". J. Neurol. Sci., 47: 93-103, 1980. I.F. 1.986

14. Cerri C, Meola G, Scarlato G: "Biochemical and morphological studies on a case of systemic

carnitine deficiency". Acta Neuropathologica, Supplementum VII, 219-220,1981. I.F. 2.165


8

15. Mariani C, Meola G, Meroni PL, Guaita C, Scarlato G: "Pentazocine-induced neuromuscular syndrome: clinical, immunological and histopathological studies in two cases". Acta Neuropathologica, Supplementum VII, 246-248, 1981. I.F. 2.165

16. Meola G, Scarpini E, Manfredi L, Mariani C, Scarlato G: "Pentazocine-blocked myogenesis in

human foetal muscle cultures". Acta Neuropathologica, Supplement VII, 310-312, 1981. I.F. 2.165

17. Meola G, Scarpini E, Silani V, Scarlato G: "Manifesting carrier of X-linked Duchenne muscular

dystrophy". J. Neurol. Sci., 49: 455-463, 1981. I.F. 1.986 18. Scarlato G, Pellegrini G, Moggio M, Meola G, Cordone G, Minetti C, Iester A: "Familial

nemaline myopathy". Neuropediatrics, 13: 211-215, 1982. I.F. 1.476 19. Meola G, Scarpini E, Minetti C, Cordone G, Scarlato G: "Studio clinico ed istomorfologico della

miopatia congenita con lesioni minime". Minerva Pediatrica, 34: 891-896, 1982. I.M. 20. Volpe P, Damiani E, Margreth A, Meola G, Scarlato G: "Immunological properties of myosin in

myotonic dystrophy". Acta Neurol. Belg., 82: 145-149, 1982. I.F. 0.521 21. Zanella A, Mariani C, Meola G, Fagnani G, Sirchia G: "Phosphofructokinase (PFK) deficiency

due to a catalytically inactive mutant M-type subunit". Am. J. Hem., 12: 215-225, 1982. I.F. 1.535

22. Lazzarin A, Parravicini CL, Meola G, Moroni M: "Aids in a italian drug addict". The Lancet,

November 17, page 1155, 1984. I.F. 13.251 23. Minetti C, Meola G, Scarpini E, Cordone G, Bado M, Scarlato G: "La miopatia con sproporzione

congenita tra i tipi di fibre". Minerva Pediatrica, 36: 181-187, 1984. I.M. 24. Meola G, Scarpini E, Manfredi L, Velicogna M, Pellegrini G, Redi CA, Scarlato G: "Infantile-

acute acid maltase deficiency (Pompe's disease): studies of muscle cultures". Basic and Applied Histochemistry, 28: 245-255, 1984. I.F. 0.959

25. Meola G, Scarpini E, Velicogna M, Mottura A, Baron PL, Beretta S, Scarlato G: "Analysis of

fibronectin expression during human muscle differentiation". Basic and Applied Histochem., 30: 153-163, 1986. I.F. 0.959

26. Rampoldi E, Meola G, Fuhrman-Conti A, Velicogna M, Larizza L: "A comparative analysis of

collagen III, IV, laminin and fibronectin in Duchenne muscular dystrophy biopsies and cell cultures". Europ. J. Cell Biol., 42: 27-34, 1986. I.F. 2.244

27. Meola G, Scarpini E, Velicogna M, Scarlato G, Larizza L, Fuhrman-Conti A: "Cytogenetic

analysis and muscle differentiation in a girl with severe muscular dystrophy". J. Neurol., 233: 168-170, 1986. I.F. 2.653

28. Scarpini E, Meola G, Baron PL, Beretta S, Velicogna M, Scarlato G: "S-100 protein and laminin:

immunocytochemical markers for human Schwann cells in vitro". Exp. Neurology, 93: 77-83, 1986. I.F. 3.503

29. Mancinelli E, Meola G, Wanke E, Velicogna M: "Duchenne muscular dystrophy (DMD): altered

acetylcholine (Ach) sensitivity in human myotubes in culture". Bollettino Società Italiana


9

Biologia Sperimentale, 62:30-34,1986. I.M. 30. Barsi L, Meola G, Velicogna M, Bonifati C, Fuhrman-Conti A, Scarlato G: "Response to DNA-

damaging agents in cultured cells from patients with X-linked Duchenne muscular dystrophy phenotype: male DMD, female DMD, possible carriers". Cytotechnology, 1:99-102,1987. I.F. 0.703

31. Bresolin N, Bet L, Moggio M, Meola G, Comi G, Gilardi A, Scarlato G: "Muscle G6PD

deficiency". The Lancet, July 25:212-213,1987. I.F. 13.251 32. Meola G, Bresolin N, Rimoldi M, Velicogna M, Fortunato F, Scarlato G: "Recessive carnitine

palmytil transferase deficiency: biochemical studies in tissue cultures and platelets". J. Neurol., 235: 74-79, 1987. I.F. 2.653

33. Scarpini E, Meola G, Baron PL, Beretta S, Velicogna M, Moggio M, Buscaglia M, Doronzo R,

Scarlato G: "Human Schwann cells: cytochemical, ultrastructural and immunological studies in vivo and in vitro". Basic &Applied Histochem., 31: 33-42, 1987. I.F. 0.959

34. Scarpini E, Kreider BQ, Lisak RP, Meola G, Velicogna M, Baron PL, Beretta S, Buscaglia M,

Ross A, Scarlato G: "Cultured of human Schwann cells isolated from foetal nerves". Brain Research, 440: 261-266, 1988. I.F. 2.489

35. Scarpini E, Baron PL, Bet L, Bottini G, Bresolin N, Meola G, Pezzoli G, Vallar G, Monza GC,

Scarlato G: "Low doses of ketazolam in anxiety: a double-blind, placebo-controlled study". Neuropsychobiology, 20: 74-77, 1988. I.F. 1.604

36. Bresolin N, Bet L, Moggio M, Meola G, Fortunato F, Comi G, Adobbati L, Geremia L, Pittalis S

Scarlato G: "Muscle glucose-6-phosphate dehydrogenase deficiency". J. Neurol., 236: 193-198, 1989. I.F. 2.653

37. Corno M, Vallar G, Scarlato G, Meola G: "Danazol and internal carotid artery thrombosis".

European Neurology, 29: 235-237, 1989. I.F. 1.179 38. Santilli I, Prelle A, Geremia L, Scarlato G, Meola G: "Nile red simultaneous staining of

intracellular lipids and membrane network in human muscle cultures". Bas. Appl. Hist., 33: 49-52, 1989. I.F. 0.959

39. Mancinelli E, Sardini A, D'Aumiller A, Meola G, Martucci G, Cossu G, Wanke E: "Properties of

acetylcholine receptor activation in human Duchenne dystrophy myotubes". Proc. Royal Soc. (London), B 237: 247-257, 1989. I.F. 2.755

40. Ponzetto C, Bresolin N, Bordoni A, Moggio M, Meola G, Bet L, Prelle A, Scarlato G: "Kearns-

Syre Syndrome: different amounts of deleted mitochondrial DNA are present in several autoptic tissues". J. Neurol. Sci., 96: 207-210, 1990. I.F. 1.986

41. Bet L, Bresolin N, Moggio M, Meola G, Prelle A, Schapira A, Binzoni T, Chomyn A, Fortunato

F, Cerretelli P, Scarlato G: "A case of mitochondrial myopathy, lactic acidosis and Complex I deficiency". J. Neurol., 237: 399-404, 1990. I.F. 2.653

42. Meola G, Mancinelli E, Geremia L, Scarlato G: "Increased acetylcholine sensitivity in Duchenne

muscular dystrophy myotubes". Ital. J. Neurol. Sci., 12: 181-185, 1991. I.F. 0.635


10

43. Meola G, Velicogna M, Brigato C, Bordoni A, Radice S, Toppi R, Bresolin N, Scarlato G: "CK-MM, PGAM-MM, G6PD and AM biochemical markers of functional innervated cultured human muscle fibers". Cytotechnology, 5 suppl. 1: 176-177, 1991. I.F. 0.703

44. Chomyn A, Meola G, Bresolin N, Lai ST, Scarlato G, Attardi G: "In vitro genetic transfer of

protein synthesis and respiration defects to mitochondrial DNA-less cells with myopathy patient mitochondria". Molecular and Cellular Biology, 11: 2236-2244, 1991. I.F. 9.836

45. Meola G: "Hereditary human myopathies in muscle culture". Italian J. Neurol. Sci., 12: 257-268,

1991. I.F. 0.635 46. Meola G, Velicogna M, Brigato C, Pizzul S, Rotondo G, Scarlato G: "Growth and differentiation

of myogenic clones from adult human muscle cell cultures". Basic Appl. Histochem., 35: 219-231, 1991. I.F. 0.959

47. Baron PL, Meola G, Scarpini E, Moggio G, Santilli I, Scarlato G: "Lysosomotropic agents

induce morphological and functional changes in human muscle cells in vitro". Basic Appl. Histochem. 35: 423-432, 1991. I.F. 0.959

48. Meola G, Rotondo G, Velicogna M, Bresolin N, Comi GP, Scarlato G: "Expression of

respiratory chain deficiencies in human cell cultures". Ital. J. Neurol. Sci., N. 13, Suppl. 1, 65-70, 1992. I.F. 0.635

49. Bresolin N, Moroni I, Meola G, Comi G, Scarlato G: "The biochemistry of mitochondrial

myopathies". Ital. J. Neurol. Sci., N. 13, Suppl. 1, 25-34, 1992. I.F. 0.635 50. Comi G, Bresolin N, Meola G, Moroni I, Gonano F, Ausenda C, Scarlato G: "Therapeutic trials

of mitochondrial encephalomyopathies". Ital. J. Neurol. Sci., N. 13, Suppl. 1, 81-86, 1992. I.F. 0.635

51. Meola G, Sansone V, Rotondo G, Radice S, Bottiroli G, Scarlato G: "Stable hybrid myotubes: a

new model for studying re-expression of enzymatic activities in vitro". Ital. J. Neurol. Sci., 14: 35-43, 1993. I.F. 0.635

52. Bresolin N, Comi GP, Fortunato F, Meola G, Gallanti A, Tajana A, Velicogna M, Gonano EF,

Ninfali P, Pifferi S, Scarlato G. "Clinical and biochemical evidence of skeletal muscle involvement in galactose-1-phosphate uridyl-transferase deficiency". J. Neurol., 240:272-277, 1993. I.F. 2.653

53. Meola G, Tremblay JP, Sansone V, Rotondo G, Radice S, Bresolin N, Huard J, Scarlato G.

"Muscle glucose-6-phosphate dehydrogenase deficiency: restoration of enzymatic activity in hybrid myotubes". Muscle & Nerve, 16:594-600,1993. I.F. 2.316

54. Sansone V, Rotondo G, Bottiroli G, Tremblay JP, Meola G "Cytoplasmic restoration and

persistence of glucose-6-phosphate dehydrogenase activity in stable hybrid myotubes". Eur. J. Histochem. 37:241-248, 1993. I.F. 0.959

55. Vita G, Toscano A, Bresolin N, Meola G, Fortunato F, Baradello A, Barbiroli B, Frassineti C,

Zaniol P, Messina C. "Muscle phosphoglycerate mutase (PGAM) deficiency in the first caucasian patient: biochemistry, muscle culture and 31P-MR spectroscopy". J. Neurol., 241: 289-294, 1994. I.F. 2.653


11

56. Meola G, Sansone V, Rotondo G, Radice S, Sterlicchio M, Mauri M, Bresolin N, Moggio M. "Neural regulation of acid maltase in an unusual adult onset deficiency". Clinical Neuropathology,13: 286-291, 1994. I.F. 0.553

57. Comi GP, Prelle A, Bresolin N, Moggio M, Bardoni A, Gallanti A, Vita G, Toscano A, Ferro

MT, Bordoni A, Fortunato F, Ciscato P, Felisari G, Tedeschi S, Castelli E, Garghentino R, Turconi A, Fraschini P, Marchi E, Negretto GG, Adobbati L, Meola G, Tonin P, Papadimitriou A, Scarlato G. Clinical variability in Becker muscular dystrophy: genetic, biochemical and immunoistochemical correlates. Brain, 117: 1-14, 1994. I.F. 7.407

58. Baron PL, Scarpini E, Meola G, Santilli I, Conti G, Pleasure D, Scarlato G. "Expression of the low affinity NGF receptor during human muscle development, regeneration, and in tissue culture. Muscle & Nerve 1994, 17: 276-284, 1994. I.F. 2.316

59. Sansone V, Rotondo G, Ptacek LJ, Meola G. "Mutation in the S4 segment of the adult skeletal

sodium channel gene in an italian paramyotonia congenita (PC) family". Ital. J. Neurol. Sci., 15:473-480, 1994. I.F. 0.635

60. Ptacek L, Tawil R, Griggs RC, Meola G, Mc Manis P, Barohn R, Mendell J, Harris C, Spitzer R,

Santiago F, Leppert MF. "Sodium channel mutations in acetazolamide-responsive myotonia congenita, paramyotonia congenita and hyperkalemic periodic paralysis". Neurology, 44:1500-1503, 1994. I.F. 5.212

61. Meola G, Sansone V, Radice S, Rotondo G, Tremblay JP. "Enzymatic activity and

morphological differentiation in de novo innervated human muscle cultures". Eur. J. Histochem., 38:125-136, 1994. I.F. 0.959

62. De Ambroggi L, Raisaro A, Marchianò V, Radice S, Meola G. Cardiac involvement in patients

with myotonic dystrophy: Characteristics features of magnetic resonance imaging. European Heart Journal , 16: 1007-1010, 1995. I.F. 5.153

63. Meola G , Sansone V, Radice S, Skradski S, Ptacek L. A family with an unusual myotonic and

myopathic phenotype and no CTG expansion (proximal myotonic myopathy syndrome): a challenge for future molecular studies. Neuromusc. Disord., 6: 143-150, 1996. I.F. 2.547

64. Meola G, Sansone V, Rotondo G, Jabbour A. Computerized tomography and magnetic

resonance muscle imaging in Miyoshi’s myopathy. Muscle & Nerve 19:1476-1480, 1996. I.F. 2.316

65. Meola G, Sansone V. A newly described myotonic disorder (Proximal myotonic myopathy -

PROMM): personal experience and review of the literature. Ital J Neurol Sci, 17:347-353, 1996. I.F. 0.635

66. Beghi E., Bogliun G., Meola G., for the Italian GBS Study Group The Guillain-Barrè Syndrome

(GBS). Ital J Neurol Sci, 17:355-361, 1996. I.F. 0.635 67. Orizio C, Esposito F, Sansone V, Parrinello G, Meola G, Veicsteinas A. Muscle surface

mechanical and electrical activities in myotonic dystrophy. Electromyography and Clinical Neurophysiology, 37: 231-239, 1997. I.M.

68. Meola G, Sansone V, Rotondo G, Tomè FMS, Bouchard JP. Oculopharyngeal muscular

dystrophy in Italy. Neuromusc. Disorders, 7, Suppl.1:S53-S56,1997. I.F. 2.547


12

69. Sansone V, Griggs RC, Meola G, Ptacek LJ, Barohn R, Iannaccone S, Bryan W, Baker N, Janas SJ, Scott W, Ririe D, Tawil R. Andersen’s syndrome: a distinct periodic paralysis. Ann Neurol, 42;305-312, 1997. I.F. 8.481

70. Meola G, Sansone V. Clinical spectrum of proximal myotonic myopathy (PROMM) syndrome.

Basic and Applied Myology, 7;317-320,1997. I.F. 0.521 71. Sansone V, Meola G. Andersen’s syndrome: a single or multiple gene channelopathy? Basic and

Applied Myology, 7; 329-331,1997. I.F. 0.521 72. Biousse V, Brown MD, Newman NJ, Allen JC, Rosenfeld J, Meola G, Wallace DC. De novo

14484 mitochondrial DNA mutation in monozygotic twins discordant for Leber’s hereditary optic neuropathy. Neurology, 49:1136-1138, 1997. I.F. 5.212

73. Moxley III RT, Udd B, Ricker K and Meola G (Italian workshop partecipant). 54th ENMC

International Workshop: PROMM (Proximal Myotonic Myopathies) and Other Proximal Myotonic Syndromes 10-12th October 1997, Naarden, The Netherlands. Neuromuscular Disorders, 8:508-518,1998. I.F. 2.747

74. Newman B, Meola G, O’Donovan DG, Schapira AHV, Kingston H. Proximal myotonic

myopathy (PROMM) presenting as myotonia during pregnancy. Neuromuscular Disorders, 9:144-9,1999. I.F. 2.747

75. Meola G, Sansone V, Perani D, Colleluori A, Cappa S, Cotelli M, Fazio F, Thornton CA,

Moxley RT. “Reduced cerebral blood flow and impaired visual-spatial function in proximal myotonic myopathy”. Neurology, 53:1042-1050, 1999. I.F. 5.212

76. Milanese C, La Mantia L, Palumbo R and the Multiple Sclerosis Centres of Lombardia, Italy

(Meola G.-Ospedale Clinicizzato, San Donato). Interferon beta treatment in relapsing-remitting multiple sclerosis: a post-marketing study in Lombardia, Italy. Ital J Neurol Sci, 20:297-302, 1999. I.F 0.635

77. Nardone A, Mazzadi C, Tiberio GAM, Spinnler P, Meola G, Giuriati G, Croci M, Tiberio G.

Colicistectomia video-laparoscopica in paziente affetta da colelitiasi in distrofia miotonica di Steinert. Ann Ital Chir, 71:139-143,2000. I.M.

78. Meola G. Clinical and genetic heterogeneity in myotonic dystrophies. Muscle Nerve. Invited

review. 23:1789-1799,2000. I.F. 2.316 79. Meola G. Myotonic dystrophies. Current Opinion in Neurology. 13:519-525,2000. I.F. 4.035 80. Meola G, Sansone V. Therapy in myotonic disorders and in muscle Chanellopathies. Neurol Sci

21:S953-S961, 2000. I.F. 0.635 81. Sansone V, Marinou K, Salvucci J, Meola G. Quantitative miotonia assessment: an experimental

protocol. Neurol Sci 21:S971-S974, 2000. I.F. 0.635 82. Meola G, Sansone V, Vitelli E, Mancuso M, Siciliano G. Proximal myotonic myopathy: Report

on Italian Families and lLterature Review. J Clin Neuromusc Dis 2:201-210,2001. I.M. 83. Beghi E. Logroscino G. Micheli A. Millul A. Perini M. Riva R. Salmoiraghi F. Vitelli E. Italian

ALS Registry Study Group (Meola G). Validity of hospital discharge diagnoses for the


13

assessment of the prevalence and incidence of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis & Other Motor Neurom Disorders. 2:99-104, 2001. I.M.

84. Meola G. Getting a grip on muscular dystrophy. Trends in Molecular Medicine. 7:583, 2001. I.F.

7.088 85. Tristani-Firouzi M, Jensen JL, Donaldson MR, Sansone V, Meola G, Hahn A, Bendahhou S,

Kwiecinski H, Fidzianska A, Plaster N, Fu YH, Ptacek LJ, Tawil R. Functional and clinical characterization of KCNJ2 mutations associated with LQT7 (Andersen syndrome). J Clin Invest 110:381-8, 2002. I.F. 14.118

86. Moxley RT 3rd, Meola G, Udd B, Ricker K. Report of the 84th ENMC workshop: PROMM

(proximal myotonic myopathy) and other myotonic dystrophy-like syndromes: 2nd workshop. 13-15th October, 2000, Loosdrecht, The Netherlands. Neuromusc Disord 12:306-17, 2002. I.F. 2.547

87. Harper PS, van Engelen BGM, Eymard B, Rogers M, Wilcox D (Meola G). 99th ENMC

International workshop: myotonic dystrophy: present management, future therapy. 9-11 November 2001, Naarden, The Netherland. Neuromusc Disord 12:596-599, 2002. I.F. 2.547

88. Meola G, Sansone V, Marinou K, Cotelli M, Moxley RT 3rd, Thornton CA, De Ambroggi L.

Proximal myotonic myopathy: a syndrome with a favourable prognosis? J Neurol Sci 193:89-96, 2002. I.F. 1.986

89. Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A, Montanari E, Zaffaroni M.

Independent Comparison of Interferon (INCOMIN) Trial Study Group. (Meola G). Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet. 359:1453-60, 2002. I.F. 18.316

90. Meola G. In memoriam: Guglielmo Scarlato, MD. Neurology 59:1304-05, 2002. I.F. 5.212 91. Beghi E., Balzarini C., Bogliun G., Logroscino G., Manfredi L., Mazzini L., Micheli A., Millul

A., Poloni M., Riva R., Salmoiraghi F., Tonini C., Vitelli E., Chiò A., Silani V., Bet L., Causarano R., Corbo M., Filippini G., Gambaro P., Testa D., Vecchio E., Perini M., Alimonti D., Ceroni M., Citterio A., Baldini D., Bonito V., Di Landro A., Moroni S., Bianchi G., Cheldi A., Delodovici M.L., Ferlito E., Porta M., La Spina I., Rezzonico M., Mariani G., Perrone P., Meola G., Romorini A., Serlenga G., Angelini C., Scarlato G., Rizzuto N., Schiffer D., Tonali P.. Reliability of the El Escorial criteria for amyotrophic lateral sclerosis. Neuroepidemiology 21:265-270, 2002. I.F. 1.390

92. Meola G. Brain's Diseases of The Nervous System, 11th edition. Donaghy M. Oxford University

Press, 2001. Neuromuscular Disorders.13:95,2003. I.F. 2.747 93. Meola G, Sansone V, Rotondo G, Mancinelli E. Muscle biopsy and cell cultures: potential

diagnostic tools in hereditary skeletal muscle channelopathies. EJH 47:17-28, 2003. I.F. 0.959 94. Milanese C, La Mantia L, Palumbo R, Martinell9i V, Murialdo A, Zaffaroni M, Caputo D, Capra

R, Bergamaschi R, the North Italy Multiple Sclerosis Group (Meola G). A post-marketing study on interferon β 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients. J Neurol Neurosurg Psychiatry 2003;74:1689-1692. . I.F. 2.939


14

95. Vihola A, Bassez G, Meola G, Zhang S, Haapasalo H, Paetau A, Mancinelli E, Rouche A, Hogrel JY, LaforA P, Maisonobe T, Pellissier JF, Krahe R, Eymard B, Udd B. Histopathological differences of myotonic dystrophy type 1 (DM1) and PROMM/DM2. Neurology. 60:1854-7, 2003. I.F. 5.212

96. Udd B, Meola G, Krahe R, Thornton C, Ranum L, Day J, Bassez G, Ricker K. Report of the

115th ENMC workshop: DM2/PROMM and other myotonic dystrophies. 3rd Workshop, 14-16 February 2003, Naarden, The Netherlands. Neuromuscul Disord. 2003;13:589-596. I.F. 2.747

97. Bachinski LL, Udd B, Meola G, Sansone V, Bassez G, Eymard B, Thornton CA, Moxley RT,

Harper PS, Rogers MT, Jurkat-Rott K, Lehmann-Horn F, Wieser T, Gamez J, Navarro C, Bottani A, Kohler A, Shriver MD, Sallinen R, Wessman M, Zhang S, Wright FA, Krahe R. Confirmation of the type 2 myotonic dystrophy (CCTG)n expansion mutation in patients with proximal myotonic myopathy/proximal myotonic dystrophy of different European origins: a single shared haplotype indicates an ancestral founder effect. Am J Hum Genet. 2003;73:835-48. I.F. 10.649

98. Meola G, Sansone V, Perani D, Scarone S, Cappa S, Dragoni C, Cattaneo E, Cotelli M, Gobbo

C, Fazio F, Siciliano G, Mancuso M, Vitelli E, Zhang S, Krahe R, Moxley RT. Executive dysfunction and avoidant personality trait in myotonic dystrophy type 1 (DM-1) and in proximal myotonic myopathy (PROMM/DM-2). Neuromuscul Disord. 2003;13:813-21. I.F. 2.747

99. L. Durelli, E.Verdun, P.Barbero, M. Bergui, E. Versino, INCOMIN Trial Study Group (Meola

G). Re: Vartanian T. An examination of the results of the EVIDENCE, INCOMIN, and phase III studies of interferon beta products in the treatment of multiple sclerosis. Clin Ther 2003; 25; 1890-1893. I.F. 2.670

100. Sallinen R, Viola A, Bachinski LL, Huoponen K, Haapasalo H, Hackman P, Zhang S, Spirito M,

Kalimo H, Meola G, Horelli-Kuitunen N, Wessman M, Krhae R, Udd B. New method for molecular diagnosis and demonstration of the (CCTG)n mutation in myotonic dystrophy type 2 (DM2). Neuromuscl Disord 2004;14:274-283. I.F. 3.340

101. Bogliun G, Beghin E for the Italian GBS Registry Study Group (Meola G). Incidence and

clinical features of acute inflammatory polyradiculoneuropathy in Lombardy, Italy, 1996. Acta Neurol Scand 2004;110:100-106. I.F. 1.982

102. Meola G, Sansone V. Treatment in myotonia and periodic paralysis. Rev Neurol

2004;160:5pt2,4S55-4S69. I.F. 0.443 103. Sansone V, Saperstein DS, Barohn RJ, Meola G. Concurrence of facioscapulohumeral muscular

dystrophy and myasthenia. Muscle Nerve 2004; 30:679-680. I.F. 2.458 104. Meola G, Moxley RT III. Myotonic dystrophy type 2 and related myotonic disorders. J Neurol

2004;251:1173-1182. I.F. 3.140 105. Sansone V, Links T, Meola G, Rose MR. Treatment for periodic paralysis (protocol for a

Cochrane review). The cochrane collaboration 2004;4:1-9. I.M. 106. Cardani R, Mancinelli E, Sansone V, Rotondo G, Meola G. Biomolecular identification of

(CCTG)n mutation in myotonic dytrophy type 2 (DM2) by FISH on muscle biopsy. Eur J Histochem. 2004;48:437-442. I.F. 0.845

107. Rotondo G, Sansone V, Cardani R, Mancinelli E, Krahe R, Stangalini D, Meola G. Proximal


15

Myotonic dystrophy (PDM) mimicking progressive muscular atrophy. Eur J Neurol 2005;12:160-161. I.F. 2.437

108. Meola G. Advanced microscopic and histochemical techniques: diagnostic tools in molecular era

of myology. Eur J Histochem 2005;49:93-96. I.F. 1.191 (IFN 1 – 22) 109. van Engelen BGM, Eymard B, Wilcox D (Meola G: Italian workshop partecipant) 123rd ENMC

International Workshop: Management and Therapy in Myotonic Dystrophy, 6-8 February 2004, Naarden, The Netherlands. Neuromuscul Disord 2005 May;15:389-94. I.F. 2.615

110. Millul A, Beghi E, Logroscino A, Vitelli E, Zardi A and "Registro Lombardo SLA" (SLALOM)

(Meola G). Survival of Patients with Amyotrophic Lateral Sclerosis in a Population-Based Registry. Neuroepidemiology 2005;25:114-119. I.F. 2.352

111. Meola G. Encefalite Acuted disseminated (ADEM) and Multiple Sclerosis (SM). Pediatr Med

Chir. 2004 May-Jun;26(3):210-1. I.M. 112. Vicart S, Sternberg D, Fontaine B, Meola G. Human skeletal muscle sodium channelopathies.

Neurol Sci 2005;26:194-202. I.F. 0.894 113. Tonelli A, D'Angelo MG, Salati R, Villa L, Germinasi C, Frattini T, Meola G, Turconi AC,

Bresolin N, Bassi MT. Early onset, non fluctuating spinocerebellar ataxia and a novel missense mutation in CACNA1A gene. J Neurol Sci. 2006 Feb 15;241(1-2):13-7. I.F. 2.315

114. Sansone V, Meola G, Perani D, Fazio F, Garibotto V, Cotelli M, Cotelli M, Vitelli E. Glucose

metabolism and dopamine PET correlates in a patient with myotonic dystrophy type 2 and parkinsonism. J Neurol Neurosurg Psychiatry. 2006;77:425-6. I.F. 3.857

115. Barbero P., Bergui M., Versino E., Ricci A., Zhong J.J., Ferrero B., Clerico M., Pipieri A.,

Verdun E., Giordano L., Durelli L., Cussi A., Genesia M.L., Festa E., Contessa G., Ghezzi A., Zaffaroni M., Cavallo R., Salvi F., Scandellari C., Stecchi S., Benedetti M.G., Moretto G., Fiumani A., Montanari E., Ludovico L., Pesce I., Tartaglione A., Parodi R.C., Nobile M., Morino U., Giuliani F., Pucci E., Cartechini E., Taus C., Urciuoli R., Giulietti M., Motti L., Meola G., Radice S., Robotti M., Toso V., Bortolon F., Milanise A., La Mantia L., Morgando E., Di Sapio A. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: Analysis of MRI responses to treatment and correlation with NAb. Mult Scler 2006;12:72-76. I.F. 2.773

116. Beghi E and EURALS Group (Meola G). 127th ENMC International Workshop: implementation

of a European Registry of ALS Naarden, The Netherlands, 8-10 October 2004. Neuromuscular Disord 2006;16:46-53. I.F. 2.667

117. Venance S.L., Cannon S.C., Fialho D., Fontaine B., Hanna M.G., Ptacek L.J., Tristani-Firouzi

M., Tawil R. and Griggs R.C ; CINCH Investigators (Meola G.) The primary periodic paralyses: Diagnosis, pathogenesis and treatment. Brain 2006;129:8-17. I.F. 8.568

118. Crippa F, Panzeri C, Martinuzzi A, Arnoldi A, Redaelli R, Tonelli C, , Baschirotto A, Vazza G,

Mostacciuolo ML, Daga A; Orso G, Profice P, Trabacca A, D’Angelo MG, Comi GP, Galbiati S, Lamperti C, Bonato S, Pandolfo M, Meola G, Musumeci O, Toscano A, Trevisan CP, Bresolin N, Bassi MT. Eight Novel Mutations in SPG4 in a Large Sample of Patients With Hereditary Spastic Paraplegia. Arch Neurol. 2006;63:750-755. I.F. 5.783


16

119. Udd B, Meola G, Krahe R, Thornton C, Ranum LPW, Bassez G, Kress W, Schoser B, Moxley R. Myotonic dystrophy DM2/PROMM and other myotonic dystrophies: 140th ENMC International Workshop with guidelines on management. Neuromuscular Disord 2006;16:403-413. I.F. 2.667

120. Ciammola A, Sassone J, Alberti L, Meola G, Mancinelli E, Russo MA, Squitieri F, Silani V.

Increased apoptosis, huntington inclusions and altered differentiation in muscle cell cultures from Huntington’s disease subjects. Cell Death and Differentiation 2006;26 May. I.F. 8.254

121. Sassone J, Ciammola A, Tiloca C, Glionna M, Meola G, Mancinelli E, Silani V. Apoptosis

induced by proteasome inhibition in human myoblast cultures. EJH 2006;50 :109-118 I.F. 1.261 122. Cappellari A, Origgi L, Spina MF, Yiannopoulou KG, Meola G, Vanoli M, Ciammola A,

Gregorini F, Scorza R, Bresolin N. Central nervous system involvement in HCV-related mixed cryologbulinemia. Electromyogr Clin Neurophysiol 2006;46:149-158. IM

123. Botta A, Bonifazi E, Vallo L, Gennarelli M, Garrè C, Salemi L, Iraci R, Sansone V, Meola G,

Novelli G. Italian guidlines for molecular analysis in myotonic dystrophies. Acta Myologica 2006;25:23-33. IM

124. Cardani RR, Mancinelli E, Rotondo G, Sansone V, Meola G. Muscleblind-like protein 1 nuclear

sequestration is a molecular path ology marker of DM1 and DM2. EJH 2006;50:177-82 I.F. 1.261

125. Meola G. Neuroimaging in the early diagnosis of Krabbe leukodystrophy types 1 and 2. Pediatr

Med Chir 2007;29:221-2. I.M. 126. Candelise L, Gattinoni M, Bersano A, Miceli G, Sterzi R, Morabito A and PROSIT Study Group

(Meola G). Stroke-unit care for acute stroke patients: an observational follow-up study. Lancet 2007;369:299-305. I.F. 25.638

127. Beghi E, Millul A, Micheli A, Vitelli E, Logroscino G and SLALOM Group (Meola G.).

Incidence of ALS in Lombardy, Italy. Neurology 2007;68:141-145 I.F. 6.014 128. Repetto C, Manenti R, Sansone V, Cotelli M, Perani A, Garibotto V, Zanetti O, Meola G,

Miniassi C. Persistent autobiographical amnesia: A case report. Behavioural Neurology 2007;1:13-17 I.F. 1,006

129. Sansone V, Gandossini S, Cotelli M, Calabria M, Zanetti O, Meola G. Cognitive impairment in

adult myotonic dystrophies: a londitudinal study. Neurol Sci 2007;28:9-15 I.F. 1,006 130. Meola G, Sansone V. Cerebral involvement in myotonic dystrophies. Muscle & Nerve

2007;36:294-306 I.F. 2.424 131. Sansone V, Piazza L, Bufera G, Meola G, Fontana A. Contrast-induced seizures after cardiac

catheterization in a 6-year-old child. Pediatr Neurol 2007;36:268-70 I.F. 1.375 132. Lanzi R, Previtali SC, Sansone V, Scavini M, Fortunato M, Gatti E, Meola G, Bosi E, Losa M.

Hypokalemic periodic paralysis in a patient with acquired growth hormone deficiency. J Endocrinol Invest 2007;30:341-345. I.F. 2.021

133. Cereda E, Sansone V, Meola G, Malavazos AE. Increased visceral adipose tissue rather than


17

BMI as a risk factor for dementia. Age Ageing 2007;36:488-491. I.F. 1.910 134. Botta A, Vallo L, Rinaldi F, Bonifazi E, Amati F, Biancolella M, Gambardella S, Mancinelli E,

Angelini C, Meola G, Novelli G. Gene expression analysis in Myotonic Dystrophy: indications for a common molecular pathogenic pathway in DM1 and DM2. Gene Expression 2007;13:339-351 I.F. 2.188

135. Meola G. IDMC-6 – The Sixth International Myotonic Dystrophy Consortium Meeting. EJH

2007;51:311-313. I.F. 1.261 136. Arnoldi A, Tonelli A, Crippa F, Villani G, Pacelli C, Sironi M, Bozzoli U, D’Angelo MG, Meola

G, Martinuzzi A, Crivella C, Redaelli F, Panzeri C, Renieri A, Comi GP, Turioni AC, Bresolin N, Bassi MT. A clinical, genetic and biochemical characterization of SPG7 mutations in a large cohort of patients with hereditary spastic paraplegia. Hum Mutat; 2008;29:532-531. I.F. 6.273

137. Sansone V, Meola G, Links T, Panzeri M, Rose M. Treatment for periodic paralysis. Cochrane

Database Syst Rev 2008; Jan 23;(1):CD005045. IF. 4.654 138. Bet L, Bareggi R, Pacei F, Bondiolotti G, Meola G, Schapira AHV. Bimodal administration of

entacapone in Parkinson’s patients improves motor control. Eur J Neurol 2008;15:268-273 IF. 2.580 (IFN 4 – 30)

139. Tricarico D, Lovaglio S, Rotondo G, Mancinelli E, Meola G, Camerino DC. Acetazolamide

prevents vacuolar myopathy in skeletal muascle of K+ -depleted rats. Br J Pharmach 2008;154:183-190. IF. 3.767

140. Durelli L, Barbero P, Bergui M, Versino E, Bassano MA, Verdun E, Rivoiro C, Ferrero C, Picco

E, Ripellino P, Giuliani G, Montanari E, Clerico M; Italian Multiple Sclerosis Study Group (Meola G.). MRI activity and neutralising antibody as predictors of response to interferon beta treatment in multiple sclerosis. J Neurol Neurosurg Psychiatry 2008;79:646-51. IF. 3.857

141. Beghi E, Millul A, Logroscino G, Vitelli E, Micheli A; for the SLALOM Group – Slalom: D.

Alimenti, D, Baldini, C. Balzarini, C. Bendotti, G. Bianchi, G. Bolgiun, V. Bomito, A,. Brambilla, L. Brunati, R. Causarano, M. Ceroni, A. Gheldi, A. Chiò, L. Chiveri, A. Citterio, M. Clerizi, G. Comi, M. Corbo, ML Delodovici, E. Donati, C Ferrarese, G Filippini, P Gambero, L Giordano, M Guidotti, I La Spina, P Liberini, G Mariani, T Pennini, G. Meola, S Moroni, E Munerati, M Perini, P Perrone, M Poloni, M Porta, A Pelle, M Rezzonico, R Riva,. A rumorini, F Sasanelli, L serlenga, mV Silani, D Testa, F Tavernelli, MC Tonini. Outcome measures and prognostic indicators in patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis 2008;9:163-167. IF. 2.754

142. Cardani R, Mancinelli E, Saino G, Bonavina L, Meola G. A putative role of ribonuclear

inclusions and MBNL1 in the impairment of gallbladder smooth muscle contractility with cholelithiasis in myotonic dystrophy type 1. Neuromuscular Disord 2008;18:641-645. I.F. 2.667

143. Lucchiari S, Pagliarani S, Corti S, Mancinelli E, Servida M, Fruguglietti E, Sansone V, Moggio

M, Bresolin N, Comi GP, Meola G. Colocalization of ribonuclear inclusions with muscle blind like-proteins in a family with myotonic dystrophy type 2 associated with a short CCTG expansion. J Neurol Sci 2008; 275:159-163. I.F. 2.315

144. Pisani V, Panico MB, Terraciano C, Bonifazi E, Meola G, Novelli G, Bernardi G, Angelini C,

Massa R. Preferential central nucleation of type 2 myofibers is an invariable feature of myotonic


18

dystrophy type 2. Muscle & Nerve 2008;38:1405-1411. I.F. 2.424 145. Sanders DB, Hart IK, Mantegazza R, Shukla SS, Siddiqi ZA, De Baets MHV, Melms A, Nicolle

MW, Solomons N, Richman DP and Investigators MSG (Meola G). An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 2008;71:400-406. I.F. 6.014

146. Matthews E, Labrum R, Sweeney MG, Sud R, Haworth A, Chinnery PF, Meola G, Schorge S,

Kullmann DM, Davis MB, Hanna MG. Voltage sensor charge loss accounts for most cases of hypokalemic periodic paralysis. Neurology 2009;72:1544-1547. I.F. 6.014

147. Meola G, Hanna MG, Fontaine B. Diagnosis and new treatment in muscle channelopathies. J

Neurol Neurosurg Psychiatry 2009;80:360-365. IF. 3.857 148. Cardani R, Baldassa s, Botta A, Rinaldi F, Novelli G, Mancinelli E, Meola G. Ribonuclear

inclusions and MBNL1 nuclear sequestration do not affect myoblast differentiation but alter gene splicing in myotonic dystrophy type 2. Neuromuscular Disord 2009;19:335-343. I.F. 2.667

149. Cardani R, Mancinelli E, Giagnacovo M, Sansone V, Meola G. Ribonuclear inclusions as

biomarker of myotonic distrophy type 2, even in improperly frozen or defrozen skeletal muscle biopsies. EJH 2009;53:97-101. I.F. 1.261

150. Chessa M, Colombo C, Butera G, Negura D, Piazza L, Varotto L, Bussadori C, Fesslova V,

Meola G and Carminati M. It is too early reccomend patent foramen ovale closure for all patients who suffer from migraine? A sinmgle-centre study. JCM 2009;10:401-405. I.F. 0.712

151. Greco S, De Simone M, Colussi C, Zaccagnini G, Fasanaro P, Pescatori M, Cardani R, Perbellini

R, Isaia E, Sale P, Meola G, Capogrossi MC, Gaetano C, and Martelli F. Common micro-RNA signature in skeletal muscle damage and regeneration induced by Duchenne muscular dystrophy and acute ischemia. FASEB J 2009;23: 3335-46. [Epub 2009 Jun 15] I.F. 6.791

152. Sansone VA, De Ambroggi G, Zanolini A, Panzeri M, Sardanelli F, Cappato R, Meola G, De

Ambroggi L. Long-term follow-up free of ventricular fibrillation recurrence after resuscitated cardiac arrest in a myotonic dystrophy type 1 patient. Europace. 2009 Sep;11:1243-4. I.F. 1.706

153. Bergamaschi R, Jarius S, Robotti M, Pichiecchio A, Wildemann B, Meola G. Two cases of

benign neuromyelitis optica in patients with celiac disease. J Neurol 2009;256:2097-2099. I.F. 2.536

154. Perdoni F, Malatesta M, Cardani R, Giagnacovo M, Mancinelli E, Meola G, Pellicciari C.

RNA/MBNL-containing foci in myoblast nuclei from patients affected by myotonia dystrophy type 2: an immunocytochemical study. Eur J Histochem 2009;53:151-158. I.F. 1.629

155. Thompson R, Schoser B, Monckton DG, Blonsky K, Lochmüller H (Meola G. - italian

partecipant for patient Registries). Patient Registries and Trial Readiness in Myotonic Dystrophy--TREAT-NMD/Marigold International Workshop Report. Neuromuscular Disord 2009;19:860-866. I.F. 2.932

156. Durelli L, Barbero P, Cucci A, Ferrero B, Ricci A, Contessa G, De Mercanti S, Ripellino P,

Lapuma D, Viglietta E, Bergui M, Versino E, Clerico M; OPTIMS Trial NAb Sub-Study Group (Meola G, Robotti M). Neutralizing antibodies in multiple sclerosis patients treated with 375


19

micrograms interferon-beta-1b. Expert Opin Biol Ther 2009;9:387-97. I.F. 3.475 157. Durelli L, Barbero P, Bergui M, Versino E, Bassano MA, Verdun E, Ferrero B, Rivoiro C,

Ferrero C, Picco E, Ripellino P, Viglietti D, Giuliani G, Montanari E, Clerico M; OPTIMS Study Group. The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders. J Neurol 2009;255:1315-23. I.F. 2.536

158. Butera G, Biondi-Zoccai GG, Carminati M, Caputi L, Usai S, Bussone G, Meola G, Delogu AB,

Sheiban I, Sangiorgi G. Systematic review and meta-analysis of currently available clinical evidence on migraine and patent foramen ovale percutaneous closure: Much ado about nothing? Catheter Cardiovasc Interv. 2010;75:494-504. I.F. 2.398

159. Vihola A, Bachinski LL, Sirito M, Olufemi SE, Hajibashi S, Baggerly KA, Raheem O,

Haapasalo H, Suominen T, Holmlund-Hampf J, Paetau A, Cardani R, Meola G, Kalimo H, Edström L, Krahe R, Udd B. Differences in aberrant expression and splicing of sarcomeric proteins in the myotonic dystrophies DM1 and DM2. Acta Neuropathol. 2010;119:465-79. I.F. 7.695

160. Sansone V, Panzeri M, Montanari M, Apolone G, Gandossini S, Rose MR, Politano L, Solimene

C, Siciliano G, Volpi L, Angelini C, Palmieri A, Toscano A, Musumeci O, Mongini T, Vercelli L, Massa R, Panico MB, Gandi M and Meola G. Italian validation of INQoL, a qualità of life questionnaire for adults with myuscle diseases. Eur J Neurol 2010;17:1178-87. I.F. 3.765

161. Micieli G, Cavallini A, Quaglini S, Fontana G, Duè M. The Lombardia Stroke Unit Registry: 1-

year experience of a web-based hospital stroke registry (Meola G - Partecipant of SUN Lombardia Collaborators). Neurol Sci 2010;31:555-64. I.F. 1.220

162. Rusconi F, Mancinelli M, Colombo G, Cardani R, Da Riva L, Borganzone I, Meola G, Zipplel

R. Protome profile in myotonia dystrophy type 2 myotubes reveals dysfunction in protein processing and mitochondrial pathways. Neurobiol Disord 2010;38:273-80. I.F. 5.121

163. Giagnacovo M, Cardani R, Meola G, Pellicciari C, Malatesta M. Routinely grozen biopsies of

human skeletal muscle are suitable for morphological and immunocytochemical analyses at transmissione electron microscopy. EJH 2010;54:e31:137-142. I.F. 1.809

164. Meola G. Myotonic dystrophies as a brain disorder. Neurol Sci 2010;31:863-4 I.F. 1.220 165. Gagnon C, Chouinard MC, Laberge L, Veillette S, Bégin P, Breton R, Jean S, Brisson D, Gaudet

D, Mathieu J; DMI Expert Panel (Meola G). Health supervision and anticipatory guidance in adult myotonic dystrophy type 1. Neuromuscular Disord 2010;20:847-51. I.F. 2.764

166. Meola G. MRI of tibialis anterior as "surrogate measure" in myotonic dystrophy type 1. Can J

Neurol Sci. 2011;38:10-1. I.F. 1.179 167. Perbellini R, Greco S, Sarra-Ferraris G, Cardani R, Capogrossi MC, Meola G, Martelli F.

Dysregulation and cellular mislocalization of specific miRNAs in myotonic dystrophy type 1. Neuromuscular Disord 2011;21:81-88. I.F. 2.764

168. Malatesta M, Meola G. Structural and functional alterations of the cell nucleus in skeletal muscle

wasting: the evidence in situ. EJH 2010;54:e44;197-199. I.F. 1.809 169. Malatesta M, Giagnacovo M, Cardani R, Meola G, Pellicciari C. RNA processing is altered in


20

skeletal muscle nuclei of patients affected by myotonic dystrophy. Histochem Cell Biol 2011;135:419-25. I.F. 4.727

170. Udd B, Meola G, Krahe R, Wansink DG, Bassez G, Kress W, Schoser B, Moxley R. Myotonic

dystrophy type 2 (DM2) and related disorders report of the 180th ENMC workshop including guidelines on diagnostics and management 3-5 December 2010, Naarden, The Netherlands. Neuromuscl Disord 2011;21:443-50. I.F. 2.764

171. Beghi E, Chiò A, Couratier P, Esteban J, Hardiman O, Logroscino G, Millul A, Mitchell D,

Preux PM, Pupillo E, Stevic Z, Swingler R, Traynor BJ, Van den Berg LH, Veldink JH, Zoccolella S; Eurals Consortium (Meola G). The epidemiology and treatment of ALS: focus on the heterogeneity of the disease and critical appraisal of therapeutic trials. Amyotroph Lateral Scler 2011 Jan;12(1):1-10. I.F. 3.390

172. Pozzilli C, Schweikert B, Ecari U, Oentrich W; BetaPlus Study group (Meola G). Supportive

strategies to improve adherence to IFN beta-1b in Multiple Sclerosis--results of the BetaPlus observational cohort study. J Neurol Sci 2011;307(1-2):120-6. I.F. 1.179

173. Jones K, Jin B, Polina I, Huichalaf C, Sarkar P, Schneider-Gold C, Schoser B, Meola G, Shyu

AB, Timchenko N, Timchenko L. RNA Foci, CUGBP1, and ZNF9 Are the Primary Targets of the Mutant CUG and CCUG Repeats Expanded in Myotonic Dystrophies Type 1 and Type 2. Am J Pathol 2011;179(5):2475-89. I.F. 5.224

174. Malatesta M, Giagnacovo M, Renna LV, Cardani R, Meola G, Pellicciari C. Cultures myoblasts

from patients affected by myotonic dystropy type 2 exhibit senescence-related features: ultrastructural evidence. EJH 2011;55:e26. I.F. 1.809

175. Sicurelli F, Mignarri A, Cardani R, Mondelli M, Carlucci A, Marino D, Meola G, Federico A,

Dotti MT. Myotonic dystrophy type 2 and autoimmune chronic gastritis: an incidental association? Neurol Sci 2011;32(6):1249-50. I.F. 1.220

176. Cardani R, Giagnacovo M, Botta A, Rinaldi F, Morgante A, Udd B, Raheem OR, Pentila S,

Suominen T, Renna LV, Sansone V, Bugiardini E, Novelli G, Meola G. Co-segregation of DM2 with a recessive CLCN1 mutation in juvenile onset of myotonic dystrophy type 2. J Neurol 2012;259(10):2090-9 I.F. 3.853

177. Ulzi G, Lecchi M, Sansone V, Redaelli E, Corti E, Saccomanno D, Pagliarani S, Corti S, Magri

F, Raimondi M, D'Angelo G, Modoni A, Bresolin N, Meola G, Wanke E, Comi GP, Lucchiari S. Myotonia congenita: novel mutations in CLCN1 gene and functional characterizations in Italian patients. J Neurol Sci 2012;318(1-2):65-71. I.F. 2.353

178. Sansone VA, Ricci C, Montanari M, Apolone G, Rose M, Meola G. INQoL Group. Measuring

quality of life impairment in skeletal muscle channelopathies. Eur J Neurol 2010;17(9):1178-87. I.F. 3.692

179. Giagnacovo M, Malatesta M, Cardani R, Meola G, Pellicciari C. Nuclear ribonucleoprotein-

containing foci increase in size in non-dividing cells from patients with myotonic dystrophy type 2. Histochem Cell Biol. 2012;138(4):699-707. I.F. 2.588

180. Greco S, Perfetti A, Fasanaro P, Cardani R, Capogrossi MC, Meola G, Martelli F. Deregulated

microRNAs in myotonic dystrophy type 2. PLoS One 2012;7(6):e39732. I.F. 4.092


21

181. Statland JM, Bundy BN, Wang Y, Rayan DR, Trivedi JR, Sansone V, Salajegheh MK, Venance

SL, Ciafaloni E, Matthews E, Meola G, Herbelin L, Griggs RC, Barohn RJ, Hanna MG, for the Consortium for Clinical Investigation of Neurologie Channelopathies. Mexiletine for Symnptoms and signs of Myotonia in Nondystrophic myotonia. JAMA 2012, October 3; Vol 308(13). I.F. 30.026

182. Jones K, Wei C, Iakova P, Bugiardini E, Schneider-Gold C, Meola G, Woodgett J, Killian J,

Timchenko NA, Timcenko LT. GSK3β mediates muscle pathology in myotonic dystrophy. J Clin Invest 2012;122(12):4461-72. I.F. 13.069

183. Meola G, Bugiardini E, Cardani R. Muscle biopsy. J Neurol. 2012;259:601-10. I.F. 3.473 184. Sansone VA, Brigonzi E, Schoser B, Villani S, Gaeta M, De Ambroggi G, Bandera F, De

Ambroggi L, Meola G. The frequency and severity of cardiac involvement in myotonic dystrophy type 2 (DM2): Long-term outcomes. Int J Cardiol 2013;168(2):1147-53. I.F. 7.078

185. Malatesta M, Giagnacovo M, Cardani R, Meola G, Pellicciari C. Human myoblasts from skeletal

muscle biopsies: in vitro culture preparations for morphological and cytochemical analyses at light and electron microscopy. Methods Mol Biol 2013;976:67-79. I.F. 1.129

186. Valaperta R, Sansone V, Lombardi F, Verdelli C, Colombo A, Valisi M, Brigonzi E, Costa E,

Meola G. Identification and Characterization of DM1 Patients by a New Diagnostic Certified Assay: Neuromuscular and Cardiac Assessments. Biomed Res Int 2013;2013:958510. Epub 2013 May 9. I.F. 2.880

187. Meola G, Jones K, Wei C, Timchenko LT. Dysfunction of protein homeostasis in myotonic

dystrophies. Histol Histopathol. 2013 Sep;28(9):1089-98. I.F. 2.281 188. Malatesta M, Giagnacovo M, Costanzo M, Cisterna B, Cardani R, Meola G. Muscleblind-loke1

undergoes ectopic relocation in the nuclei of skeletal muscles in myotonic dystrophy and sarcopenia. Eur J Histochem 2013; 57:e15. I.F. 2.412

189. Passeri E, Bugiardini E, Sansone VA, Valaperta R, Costa E, Ambrosi B, Meola G, Corbetta S.

Vitamin D, parathyroid hormone and muscle impairment in myotonic dystrophies. J Neurol Sci. 2013 Aug 15;331(1-2):132-5. I.F. 2.243

190. Meola G. Myotonic dystrophy is not only a disease affecting the muscles, it is also a CNS

disorder. Eur J Neurol 2014;21(2):183-4. I.F. 4.162 191. Gagnon C, Meola G, Hébert LJ, Puymirat J, Laberge L, Leone M. Report of the first Outcome

Measures in Myotonic Dystrophy type 1 (OMMYD-1) international workshop: Clearwater, Florida, November 30, 2011. Neuromuscul Disord. 2013 Dec;23(12):1056-68. I.F. 3.464

192. Sansone VA, Brigonzi E, Schoser B, Villani S, Gaeta M, De Ambroggi G, Bandera F, De

Ambroggi L, Meola G. The frequency and severity of cardiac involvement in myotonic dystrophy type 2 (DM2): long-term outcomes. Int J Cardiol 2013;168(2):1147-53. I.F. 5.509

193. Galeotti F, Massari M, D'Alessandro R, Beghi E, Chiò A, Logroscino G, Filippini G, Benedetti

MD, Pugliatti M, Santuccio C, Raschetti R; ITANG study group (Meola G). Risk of Guillain-Barré syndrome after 2010-2011 influenza vaccination. Eur J Epidemiol. 2013;28(5):433-44. I.F. 5.118


22

194. ACST-2 Collaborative Group (Meola G), Halliday A, Bulbulia R, Gray W, Naughten A, den

Hartog A, Delmestri A, Wallis C, le Conte S, Macdonald S. Status update and interim results from the asymptomatic carotid surgery trial-2 (ACST-2). Eur J Vasc Endovasc Surg 2013;46(5):510-8. I.F. 2.820

195. Cardani R, Bugiardini E, Renna LV, Rossi G, Colombo G, Valaperta R, Novelli G, Botta A,

Meola G. Overexpression of CUGBP1 in Skeletal Muscle from Adult Classic Myotonic Dystrophy Type 1 but Not from Myotonic Dystrophy Type 2. PLoS One. 2013;8(12):e83777. I.F. 3.730

196. Meola G. Clinical aspects, molecular pathomechanisms and management of myotonic

dystrophies. Acta Myol. 2013;32:154-65. Review. I.M. 197. Lunetta C, Sansone VA, Penco S, Mosca L, Tarlarini C, Avemaria F, Maestri E, Melazzini MG,

Meola G, Corbo M. Amyotrophic lateral sclerosis in pregnancy is associated with a vascular endothelial growth factor promoter genotype. Eur J Neurol 2014;21(4):594-8. I.F. 4.162

198. Bugiardini E, Meola G, on behalf of the DM-CNS Group. Consensus on cerebral involvement in

myotonic dystrophy Workshop report: May 24-27, 2013, Ferrere (AT), Italt. Neuromuscular Disord 2014 [Epub ahead of print] I.F. 3.464

199. Canavero I, Cavallini A, Perrone P, Magoni M, Sacchi L, Quaglini S, Lanzola G, Micieli G;

Lombardia Stroke Registry (LSR investigators - Meola G). Clinical factors associated with statins prescription in acute ischemic stroke patients: findings from the Lombardia Stroke Registry. BMC Neurol. 2014 Mar 21;14:53. I.F. 2.564

200. Perfetti A, Greco S, Bugiardini E, Cardani R, Gaia P, Gaetano C, Meola G, Martelli F. Plasma

microRNAs as biomarkers for myotonic dystrophy type 1. Neuromuscul Disord. 2014 Jun;24(6):509-15. I.F. 3.464

201. Perfetti A, Greco S, Fasanaro P, Bugiardini E, Cardani R, Manteiga JM, Riba M, Cittaro D,

Stupka E, Meola G, Martelli F. Genome wide edentification of aberranr alternative splicing events in myotonic dystrophy type 2. PLoS One. 2014 Apr 10;9:e93983. I.F. 3.730

202. Meola G, Cardani R. Myotonic dystrophies: an update on clinical aspects, genetic, pathology,

and molecular pathomecanisms. Biochim Biophys Acta 2014;May 29 pii: S0925-4439(14)00147-1. doi: 10.1016/j.bbadis.2014.05.019. [Epub ahead of print]. I.F. 5.089

203. Malatesta M, Cardani R, Pellicciari C, Meola G. RNA Transcription and Maturation in Skeletal

Muscle Cells are Similarly Impaired in Myotonic Dystrophy and Sarcopenia: The Ultrastructural Evidence. Front Aging Neurosci. 2014 Jul 30;6:196(1-4). I.F. 2.843

204. Cardani R, Giagnacovo M, Rossi G, Renna LV, Bugiardini E, Pizzamiglio C, Botta A, Meola G.

Progression of muscle histopathology but not of spliceopathy in myotonic dystrophy type 2. Neuromuscul Disord. 2014 Jun 25. pii: S0960-8966(14)00601-4. doi:10.1016/j.nmd.2014.06.435. [Epub ahead of print]. I.F. 3.134

205. Klinck R, Fourrier A, Thibault P, Toutant J, Durand M, Lapointe E, Caillet-Boudin ML,

Sergeant N, Gourdon G, Meola G, Furling D, Puymirat J, Chabot B. RBFOX1 Cooperates with MBNL1 to Control Splicing in Muscle, Including Events Altered in Myotonic Dystrophy Type 1. PLoS One. 2014 Sep 11;9(9):e107324. doi: 10.1371/journal.pone.0107324. eCollection 2014.


23

PMID: 25211016 [PubMed - as supplied by publisher]. I.F. 3.534 206. Renna L.V., Cardani R, Botta A, Rossi G, Fossati B, Costa E, Meola G. Premature senescenze in

primary muscle cultures of myotonic dystrophy type 2 is not associated qith p16 unduction. Eur J Histochem 2014:58:2444 (pagg. 275-286). I.F. 2.412

207. Bugiardini E, Rivolta I, Binda A, Soriano Caminero A, Cirillo F, Cinti A, Giovannoni R, Botta

A, Cardani R, Wicklund MP, Meola G. SCN4A mutation as modifying factor of myotonic dystrophy type 2 phenotype. Neuromuscul Disord. 2015 Apr;25(4):301-7 I.F. 2.638

208. Gagnon C, Meola G, Hébert LJ, Laberge L, Leone M, Heatwole C. Report of the second

Outcome Measures in Myotonic Dystrophy type 1 (OMMYD-2) international workshop San Sebastian, Spain, October 16, 2013.Neuromuscul Disord. 2015 Jul;25(7):603-16. I.F. 2.638

209. Passeri E, Bugiardini E, Sansone VA, Pizzocaro A, Fulceri C, Valaperta R, Borgato S, Costa E,

Bandera F, Ambrosi B, Meola G, Persani L, Corbetta S. Gonadal failure is associated with visceral adiposity in myotonic dystrophies. Eur J Clin Invest. 2015 May 7. doi: 10.1111/eci.12459. [Epub ahead of print] I.F. 2.734

210. Jones K, Wei C, Schoser B, Meola G, Timchenko N, Timchenko L. Reduction of toxic RNAs in

myotonic dystrophies type 1 and type 2 by the RNA helicase p68/DDX5. Proc Natl Acad Sci U S A. 2015 Jun 15. pii: 201422273. [Epub ahead of print] I.F. 9.674

211. Meola G and Cardani R. Myotonic Dystrophy type 2: an update on clinical aspects, genetic and pathomolecular mechanism. BBA-MOL BASIS DIS. 2015;1852:594-606 I.F. 4.882

212. Benedetti MD, Pugliatti M, D'Alessandro R, Beghi E, Chiò A, Logroscino G, Filippini G, Galeotti F, Massari M, Santuccio C, Raschetti R; ITANG Study Group (Meola G). A Multicentric Prospective Incidence Study of Guillain-Barré Syndrome in Italy. The ITANG Study. Neuroepidemiology. 2015;45:90-99 I.F. 2.558

213. Bosco G, Diamanti S, Meola G; DM-CNS Group. Workshop Report: consensus on biomarkers of cerebral involvement in myotonic dystrophy, 2-3 December 2014, Milan, Italy. Neuromuscul Disord 2015;25:813-23 I.F. 2.638

214. Meola G, Cardani R. Myotonic Dystrophy type 2: an update on clinical aspects, genetic and pathomolecular mechanism. BBA-Mol Basis Dis 2015;1852:594-606. I.F. 4.882

215. Esposito F, Cè E, Rampichini S, Limonta E, Venturelli M, Monti E, Bet L, Fossati B, Meola G.

Electromechanical delay components during skeletal muscle contraction and relaxation in patients with myotonoic dystrophy type 1. Neuromuscul Disord. 2016;26(1):60-72. I.F. 2.309

216. Lanzillo R, Quarantelli M, Pozzilli C, Trojano M, Amato MP, Marrosu MG, Francia A, Florio C,

Orefice G, Tedeschi G, Bellantonio P, Annunziata P, Grimaldi LM, Comerci M, Brunetti A, Bonavita V, Alfano B, Marini S, Brescia Morra V; ARIANNA study group (Meola G). No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1a therapy in relapsing-remitting multiple sclerosis (the ARIANNA study). Mult Scler. 2015 Oct 14. pii: 1352458515611222. [Epub ahead of print] I.F. 4.822

217. Lunetta C, Lizio A, Sansone VA, Cellotto NM, Maestri E, Bettinelli M, Gatti V, Melazzini

MG, Meola G, Corbo M. Strictly monitored exercise programs reduce motor deterioration in ALS: preliminary results of a randomized controlled trial. J Neurol. 2015 Oct 17. [Epub ahead of


24

print]. I.F. 3.377 218. Valaperta R, Lombardi F, Cardani R, Fossati B, Brigonzi E, Merli I, Sansone V, Merletti G,

Spina E, Meola G, Costa E. Development and Validation of a New Molecular Diagnostic Assay for Detection of Myotonic Dystrophy Type 2. Genet Test Mol Biomarkers. 2015;19(12):703-9. I.F. 1.464

219. Iachettini S, Valaperta R, Marchesi A, Perfetti A, Cuomo G, Fossati B, Vaienti L, Costa

E, Meola G, Cardani R. Tibialis anterior muscle needle biopsy and sensitive biomolecular methods: a useful tool in myotonic dystrophy type 1. Eur J Histochem. 2015;26;59(4):2562. I.F. 2.042

220. Sansone VA, Burge J, McDermott MP, Smith PC, Herr B, Tawil R, Pandya S, Kissel J, Ciafaloni

E, Shieh P, Ralph JW, Amato A, Cannon SC, Trivedi J, Barohn R, Crum B, Mitsumoto H, Pestronk A,Meola G, Conwit R, Hanna MG, Griggs RC; Muscle Study Group. Randomized, placebo-controlled trials of dichlorphenamide in periodic paralysis. Neurology. 2016 Feb 10. pii: 10.1212/WNL.0000000000002416. [Epub ahead of print]. I.F. 8.185

Capitoli di libri e monografie in lingua inglese

1. Albizzati MG, Bassi S, Cerri C, Frattola L, Meola G: "Gangliosides in denervation: an experimental and clinical study". In "Peripheral Neuropathies". Canal N, Pozza G (Eds) - Elsevier - North Holland, 453-458, 1978.

2. Scarlato G, Pellegrini G, Moggio M, Meola G, Frattola L: "Carnitine deficiency and lipid storage

myopathy in three patients: analysis of some differential features". Perspectives in Inherited Metabolic Diseases, 3:109-128, 1979.

3. Bresolin N, Meola G, Bet L, Martucci G, Fortunato F, Comi G, Adobbati L, Moggio M, Scarlato

G: "A new muscle enzyme defect: glucose-6-phosphate dehydrogenase deficiency". In "Advances in myochemistry" Ed. (G. Benzi) - John Libbey Eurotext - London - Paris: 397-398, 1987.

4. Meola G, Bresolin N, Velicogna M, Chianese L, Moggio M, Fortunato F, Scarlato G:

"Ubidecarenone treatment protects KSS myotubes exposed to 2-4 DNP". In "Advances in myochemistry" Ed. (G. Benzi) - John Libbey Eurotext - London - Paris: 403-404, 1987.

5. Meola G, Barsi L, Velicogna M, Scarlato G, Fuhrman-Conti A: "Cytogenetic analysis and

response to ionising radiations in a girl with severe muscular dystrophy". Molecular Genetics of Neurological and Neuromuscular Disease - Ed. S. Di Donato, S. Di Mauro, A. Mamoli, L.P. Rowland. (Raven Press - Advance in Neurology), vol. 48: 175-188, 1988.

6. Meola G, Velicogna M, Doronzo R, Scarpini E, Baron PL, Beretta S, Buscaglia M, Chianese L,

Scarlato G: "Vital freezing of human Schwann cells for storage and reculture". In "Peripheral Nerve Development and Regeneration" Ed. E. Scarpini, M.G. Fiori, D. Pleasure, G. Scarlato, Liviana Press, Padova, vol. 19: 75-79, 1989.

7. Federico A, Malandrini A, Scarpini E, Costantino-Ceccarini E, Meola G, Volpi N, Conti G,

Scarlato G, Guazzi GC: "Biochemical and tissue culture studies of nerve in Tomaculous neuropathy". Peripheral nerve development: recent advances and clinical applications. Scarpini E, Fiori MG, Pleasure D, Scarlato G (Eds). Fidia Research Series, vol. 19: 275-281, Liviana


25

Press, Padova, 1989. 8. Meola G, Velicogna M, Bresolin N, Geremia L, Fortunato F, Moggio M, Longo A, Scarlato G:

"Effects of COQ10 on muscle cells from patients with mitochondrial myopathies and CPEO". Proc. "Biomedical and Clinical aspects of coenzyme Q". K. Folkers, G.P. Littarru, T. Yamagami (Eds.). Elsevier Science Publishers, 383-396, 1991.

9. Bresolin N., Moroni I, Ciafaloni E, Moggio M, Meola G, Gatti A, Comi G and Scarlato G.

Familiar cases of mitochondrial myopathies: mitochondrial DNA deletions and genetic analysis. Molecular basis of Neurological Disorders and their Treatment. J.W. Gorrod, Albano O, Ferrari E and Papa S, (Eds.); cap. 22, 228-242, 1992.

10. Meola G, Sansone V. The role of EEG in brainstem and cerebellar lesions. In Equilibrium

Disorders. Brainstem and cerebellar pathology. A. Cesarani, D. Alpini (Eds.), pagg 81-83, Springer 1994.

11. Meola G, Sansone V. The neurological point of view. In Whiplash injuries. Diagnosis and

treatment. A. Cesarani A, Alpini D, Boniver R, Claussen CF, Gagey PM, Magnusson L, Ödkvist LM (Eds.), pagg 38-41, Springer 1996.

12. Meola G and Moxley RT III. Myotonic disorders: myotonic dystrophy, promm. In Muscle

Diseases - Blue Books of Neurology, Eds. Schapira AHV and R.C. Griggs. Butterworth Heinemann, Boston; chapter 5;115-134, 1999.

13. Griggs RC, Sansone V, Meola G, Moxley RT III. Exercise intolerance and muscle pain in

myotonic disorders. In Exercise intolerance and muscle contracture. Eds G. Serratrice,J. Pouget, J-Ph Azulay. Springer;133-141, 1999.

14. Moxley RT and Meola G. Myotonic dystrophy. In “Monographs in Clinical Neuroscience”

Neuromuscular Diseases: from basic mechanisms to clinical menagement. Ed F.Deymeer. Karger 2000. pagg.61-78.

15. Meola G, Karpati G and Griggs RC. The Principles of Treatment, Prevention and Rehabilitation:

Perspectives on Future Treatment. In “Disorders of voluntary muscle”. Eds (G. Karpati, D. Hilton-Jones, R.C. Griggs). Chapter 36. Cambridge University Press. 2001.

16. Moxley RT and Meola G. The Myotonic dystrophies. In “Molecular and Genetic Basis of

Neurological and Psychiatric Disease” Eds (RN Rosenberg, SB Prusiner, S DiMauro, RL Barchi, EJ Nestler). Butterworth Heinemann – Philadelphia. Chapter 47; 511-518, 2003, 3rd Ed.

17. Meola G and Hilton-Jones D. Diagnosis and baseline investigation in myotonic dystrophy: a core

protocol. In “Myotonic Dystrophy: present management, future therapy”. Eds (Harper PS, van Engelen B, Eymard B, Wilcox DE). Oxford University press. Oxford, UK. Chapter 3;39-48, 2004, 1st Ed.

18. Hilton-Jones D, Maxwell D and Meola G. Somnolence and its management. In “Myotonic

Dystrophy: present management, future therapy”. Eds (Harper PS, van Engelen B, Eymard B, Wilcox DE). Oxford University press. Oxford, UK. Chapter 12;135-149, 2004, 1st Ed.

19. Sansone V, Meola G. Dementia in neuromuscular disorders. In “Secondary dementias”. Ed R.

Kurlan. Marcel Dekker, NY. 2004.


26

20. Meola G, Sansone V. Management and rehabilitation. In “Management and rehabilitation to immunological and inflammatory disorders of peripheral nerve and muscle”. Eds (L Ginsberg, R Orrell). Elsevier 2004. In press.

21. Moxley RT and Meola G. The Myotonic dystrophies. In “Molecular and Genetic Basis of

Neurological and Psychiatric Disease” Eds (RN Rosenberg, S DiMauro, HL Paulson, L Ptacek and EJ Nestler). Wolters Kluwer / Lippincott Williams & Wilkins – Philadelphia. Chapter 47; 532-541, 2008, 4th Ed.

22. Meola G and Cardani R. RNA-binding proteins in myotonic dystrophies. In “RNA Binding

Proteins in Development and Disease”. Ed Robert B. Denman. 2008:153-166. 23. Winblad S, Ekstöm AB, Meola G. Myotonic Dystrophy. In “Cognitive and Behavioral

abnormalities of pediatric diseases”. Ed Ruth D. Nass and Yitzchak Frank. Oxford University Press - NY 2010:499-506.

24. Moxley RT, Hilbert JE, Meola G. The Myotonic dystrophies. In “Rosemberg’s Molecular and

Genetic Basis of Neurological and Psychiatric Disease” Eds (RN Rosenberg, Pascual JM). Academic Press is an imprint of Elsevier – San Diego, CA. Chapter 96:1153-68, 2015, 5th Ed.

25. Meola G, Bugiardini E. Myotonic Dystrophy. Medlink Neurology, 2013 26. Meola G, Bugiardini E, Scelzo E. Neurology of Whiplash. In “Whiplash Injuries, Diagnosis and

Treatment” Eds DC Alpini, G Brugnoni, A Cesarani. Springer-Verlag Italia, Chapter 5;55-64, 2014, 2nd Ed.

27. Meola G, Cardani R. Myotonic Dystrophies. International Neurology. Elsevier Ed. 2014. 28. Meola G, Cardani R. Di Mauro S. Myotonic Dystrophy. MedLink Neurology 2015.

www.medlink.com Febbraio 2016

Documents

Prof. Giovanni Meola - lamadonnina.grupposandonato.it · curriculum vitae prof. giovanni meola 1 curriculum vitae et studiorum giovanni meola professore ordinario di neurologia universitÀ